Literature DB >> 19230789

Image-guided intracavitary high-dose-rate brachytherapy for cervix cancer: A single institutional experience with three-dimensional CT-based planning.

Brian Wang1, Alexander Kwon2, Yunping Zhu2, Inhwan Yeo2, Clarissa F Henson3.   

Abstract

PURPOSE: To evaluate and report volumetric dose specification of clinical target volume (CTV) and organs at risk with three-dimensional CT-based brachytherapy. In this study, we analyzed CTV volumes and correlated the dose specification from CT-based volumes with doses at classical point A and International Commission on Radiation Units and Measurements (ICRU) points. METHODS AND MATERIALS: Ten patients who underwent definitive high-dose-rate brachytherapy for cervical cancer between May 2006 and March 2007 were retrospectively identified for this study. Each patient underwent five intracavitary insertions with CT-compatible ring and tandem applicators using a universal cervical Smit sleeve. Dose of 6.0Gy per fraction was prescribed to the 100% isodose line. The dose distribution was modified using the feature of "geometry optimization" to achieve maximum CTV coverage and to spare the organs at risk. The minimal doses for most irradiated 2, 1, 0.1cm(3) of bladder (D(BV2) , D(BV1), and D(BV0.1)) and rectum (D(RV2), D(RV1), and D(RV0.1)) were determined from dose-volume histograms and were compared with the doses estimated at the ICRU reference points.
RESULTS: The mean CTV of the 10 patients had a shrinkage trend over the five fractions, with a mean of 77.4cm(3) from the first fractions and a mean of 65.5cm(3) from the last fractions (r=-0.911, p=0.031). CTV volumes directly correlated with dose to point A (r=0.785, p=0.007). Eight of 10 patients achieved an average dose received by at least 90% of volume (D(90)) >/=6.0Gy. For bladder, the doses determined from the 3-dimensional (3D) plan correlated significantly with the doses to the ICRU reference bladder point, for example, D(BV2) (r=0.668, p<0.001), D(BV1) (r=0.666, p<0.001), and D(BV0.1) (r=0.655, p<0.001). However, for rectum, the estimated doses to the ICRU reference rectal point did not correlate significantly with doses determined from 3D plan, for example, D(RV2) (r=0.251, p=0.079), D(RV1) (r=0.279, p=0.049), and D(BV0.1) (r=0.282, p=0.047).
CONCLUSIONS: Our experience showed that excellent dose coverage of CTV can be achieved with image-guided CT-based planning with geometric optimization although maximal sparing of rectum was not achieved. Careful dose constraints and standardization of D(90) should be considered when optimizing doses to target tissues such that normal tissue constraints can be met.

Entities:  

Mesh:

Year:  2009        PMID: 19230789     DOI: 10.1016/j.brachy.2008.10.004

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  10 in total

1.  Can point doses predict volumetric dose to rectum and bladder: a CT-based planning study in high dose rate intracavitary brachytherapy of cervical carcinoma?

Authors:  V M Patil; F D Patel; S Chakraborty; A S Oinam; S C Sharma
Journal:  Br J Radiol       Date:  2011-05       Impact factor: 3.039

Review 2.  Imaging strategies in the management of oesophageal cancer: what's the role of MRI?

Authors:  Peter S N van Rossum; Richard van Hillegersberg; Frederiek M Lever; Irene M Lips; Astrid L H M W van Lier; Gert J Meijer; Maarten S van Leeuwen; Marco van Vulpen; Jelle P Ruurda
Journal:  Eur Radiol       Date:  2013-02-13       Impact factor: 5.315

3.  3D-CT implanted interstitial brachytherapy for T2b nasopharyngeal carcinoma.

Authors:  Yu-Feng Ren; Yuan-Hong Gao; Xin-Ping Cao; Wei-Jun Ye; Bin S Teh
Journal:  Radiat Oncol       Date:  2010-11-23       Impact factor: 3.481

4.  Current situation of high-dose-rate brachytherapy for cervical cancer in Brazil.

Authors:  Rogério Matias Vidal da Silva; Juliana Castro Dourado Pinezi; Luiz Eduardo Andrade Macedo; Divanízia do Nascimento Souza
Journal:  Radiol Bras       Date:  2014 May-Jun

5.  Evaluation of different magnetic resonance imaging contrast materials to be used as dummy markers in image-guided brachytherapy for gynecologic malignancies.

Authors:  Camila Pessoa Sales; Heloisa de Andrade Carvalho; Khallil Chaim Taverna; Bruno Fraccini Pastorello; Rodrigo Augusto Rubo; Arthur Felipe Borgonovi; Silvia Radwanski Stuart; Laura Natal Rodrigues
Journal:  Radiol Bras       Date:  2016 May-Jun

6.  Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses.

Authors:  Cem Onal; Gungor Arslan; Erkan Topkan; Berrin Pehlivan; Melek Yavuz; Ezgi Oymak; Aydin Yavuz
Journal:  J Exp Clin Cancer Res       Date:  2009-07-01

7.  Mapping of dose distribution from IMRT onto MRI-guided high dose rate brachytherapy using deformable image registration for cervical cancer treatments: preliminary study with commercially available software.

Authors:  Hayeon Kim; M Saiful Huq; Chris Houser; Sushil Beriwal; Dariusz Michalski
Journal:  J Contemp Brachytherapy       Date:  2014-06-03

8.  Dosimetric Comparison between Three-Dimensional Magnetic Resonance Imaging-Guided and Conventional Two-Dimensional Point A-Based Intracavitary Brachytherapy Planning for Cervical Cancer.

Authors:  Juan Ren; Wei Yuan; Ruihua Wang; Qiuping Wang; Yi Li; Chaofan Xue; Yanli Yan; Xiaowei Ma; Li Tan; Zi Liu
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

9.  Concurrent Chemo- Radiobrachytherapy with Cisplatin and Medium Dose Rate Intra- Cavitary Brachytherapy for Locally Advanced Uterine Cervical Cancer

Authors:  Mahdi Aghili; Bahram Andalib; Zhaleh Karimi Moghaddam; Afsaneh Maddah Safaie; Farnaz Amoozgar Hashemi; Nima Mousavi Darzikolaie
Journal:  Asian Pac J Cancer Prev       Date:  2018-10-26

10.  Preliminary report of a single-channel applicator in high dose rate afterloading brachytherapy for cervical cancer.

Authors:  Dan Li; En Wen; Yingjie Zhang; Zhouxue Wu; Haowen Pang; Peirong Ren; Changling Shang; Lijia He; Jianwen Zhang; Li Xiang; Hongru Yang; Qiaoli Liu; Qinglian Wen; Juan Fan; Sheng Lin; Jingbo Wu
Journal:  Cancer Sci       Date:  2018-11-28       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.